Human ribosomes interactions reveal the binding landscape of neomycin
By integrating Cryo-EM and functional assays, this study reveals that while neomycin binds extensively to human ribosomes in vitro, its cellular binding landscape is significantly altered with minimal impact on global protein synthesis, instead causing widespread stop-codon readthrough that highlights a disconnect between structural binding and functional toxicity.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Inside every living cell, tiny machines called ribosomes act as the assembly lines for life. Their job is to read genetic instructions and stitch together proteins, the complex molecules that build and run our bodies. These machines are so fundamental that bacteria and humans both use them, though their versions are slightly different. Because of this similarity, a class of powerful antibiotics known as aminoglycosides, which includes a drug called neomycin, works by jamming the bacterial ribosome to stop infection. However, this same mechanism can accidentally jam the human version, leading to serious side effects like hearing loss and kidney damage. For decades, scientists have operated under a specific assumption: that the reason these drugs hurt us is that they bind tightly to our mitochondrial ribosomes—the ancient, bacteria-like machines inside our cells that power our energy supply. This idea has guided how we understand drug toxicity, but it has relied heavily on what happens when scientists mix drugs and ribosomes in a test tube, far removed from the complex, crowded environment of a living cell.
A new study challenges this long-held view by looking directly at what happens when human cells are exposed to neomycin. The researchers, led by a team at Shandong University, combined high-resolution imaging with functional tests to map exactly where the drug lands on human ribosomes and what it actually does to the cell. They started by examining the ribosomes in isolation, treating them with neomycin in a controlled laboratory setting. Using a powerful imaging technique called cryo-electron microscopy, which allows scientists to see individual atoms, they discovered that neomycin is a very busy molecule. When placed in a test tube, it latches onto dozens of different spots on both the mitochondrial ribosomes and the main cytoplasmic ribosomes that make most of our proteins. It binds to the decoding center, the critical area where the machine checks if the genetic code is correct, and it sticks to many other peripheral locations as well. In this artificial environment, the drug appears to be everywhere, suggesting it should be a potent disruptor of human protein production.
However, the story changes dramatically when the researchers moved from the test tube to living cells. They treated human cells with neomycin and then carefully isolated the ribosomes to see what the drug was actually doing inside the body. Surprisingly, when they looked at the mitochondrial ribosomes recovered from these treated cells, the drug was nowhere to be found. Despite the fact that the cells had absorbed a significant amount of neomycin, the drug did not remain stuck to the mitochondrial machines. Similarly, on the main cytoplasmic ribosomes, the drug was present at only a few of the many sites it occupied in the test tube, and it was completely absent from the critical decoding center. This finding suggests that the crowded, complex environment inside a living cell prevents the drug from settling into the many spots it easily occupies in a simple solution. The drug may bind briefly or weakly, but it does not stay put long enough to be seen after the cell is processed.
The most striking part of the discovery is what the drug actually did to the cells while it was there. If neomycin were truly jamming the ribosomes as the old model suggested, the cells should have stopped making proteins or died in large numbers. Instead, the researchers found that the cells continued to produce proteins at normal rates. The mitochondria kept working, and the main protein factories kept churning out their products. The drug did not shut down the assembly lines. However, it did introduce a subtle but specific error. While the overall speed of production remained steady, the drug caused the ribosomes to occasionally ignore the "stop" signals in the genetic code. This led to a phenomenon called readthrough, where the machine kept going past the intended end of a message, creating slightly longer, potentially faulty proteins. This effect was widespread, occurring across thousands of different genes, including those vital for mitochondrial function.
The study concludes that the relationship between the drug and the human ribosome is far more nuanced than previously thought. The extensive binding seen in test tubes does not translate to the same behavior inside a living cell, where the drug fails to stick to the mitochondrial ribosomes and only partially occupies the main ones. The toxicity and side effects of neomycin, therefore, likely do not come from a total shutdown of protein synthesis or a simple jamming of the mitochondrial engine. Instead, the damage appears to stem from a subtle loss of precision, where the drug causes the cellular machinery to misread instructions and produce proteins that are slightly too long. This shift in understanding highlights that the environment inside a cell is a powerful filter, changing how drugs interact with their targets. It suggests that to truly understand how medicines work and why they might harm us, we must look beyond the clean simplicity of a test tube and observe the messy, dynamic reality of the living cell.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.